In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until sickness progression or the contributors are unable to tolerate the study drugs. and after that advertise H3K27Ac at this region. Chromatin hyperacetylation could boost https://mauricet009juf3.dekaronwiki.com/user